Palisade Bio, Inc. (NASDAQ: PALI) is a Healthcare company (Biotechnology) with a market capitalization of $181M. The Maz Rating grades it against the other companies in its sector.
Palisade Bio, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.01, Palisade Bio, Inc. trades at 360.3x sales and 1.9x book value. Over the last twelve months it generated about $502488 of revenue and a net loss of $40M. It runs an operating margin of -9625.4% and a net margin of -8739.2%. It shows return on equity of -35.6%, return on invested capital of -42.7% and a free cash flow yield of -14.6%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 20.16. Over the past 52 weeks the share price ranged from $0.99 to $2.86, with a beta of 1.62.
Palisade Bio, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 5 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Palisade Bio, Inc. (PALI) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global and Dow Jones, and fails AAOIFI, MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 31.4% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 31.4% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 31.4% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.01% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 98.3% / 33.33% · Receivables / Avg Assets (4Q) 0.15% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 95.8% / 33.33% · (Cash+Recv) / Total Assets 95.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Palisade Bio, Inc. (PALI) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global and Dow Jones, and fails AAOIFI, MSCI and FTSE.
No. Palisade Bio, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Palisade Bio, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.